1. The Evolving Treatment Landscape in Atopic Dermatitis

2. Introduction

3. Pathomechanisms of AD

4. IL-4 and IL-13 Further Impair Barrier Function: A Vicious Cycle

5. New Therapeutic Targets for AD

6. Evolution of Treatment Landscape in AD

7. Key Challenges in Managing Patients With AD

8. Evolution of Treatment Landscape in AD (cont)

9. Current Therapy Recommendations for Patients With AD

10. Current Therapy Recommendations for Patients With AD (cont)

11. Real-World Use of Immunosuppressant Therapies for AD

12. Use of Systemic Therapies in Patients With AD

13. Dupilumab AD Clinical Development Phase 3 Program

14. SOLO-1 and SOLO-2: Primary and Secondary Endpoints

15. SOLO-1 and SOLO-2: Pruritus

16. SOLO-1 and SOLO-2: Primary and Secondary Endpoints (cont)

17. CHRONOS: Efficacy Over 52 Weeks

18. CHRONOS: Sustained Improvements in IGA 0/1 Through 52 Weeks

19. CAFÉ: Primary Endpoint

20. CAFÉ: Secondary Endpoints at Week 16

21. Effect of Dupilumab on Quality of Life

22. Dupilumab: Safety

23. Agents Under Investigation

24. Conclusions

25. Abbreviations

26. Abbreviations (cont)